TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | 1068.22% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 06/07/2022 | 1847.04% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2022 | 1068.22% | HC Wainwright & Co. | 10 美元 → 6 美元 | 维护 | 买 |
| 2022 年 7 月 6 日 | 1847.04% | HC Wainwright & Co. | → 10 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for TransCode Therapeutics (RNAZ)?
TransCode Therapeutics (RNAZ) 的目标价格是多少？
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on November 15, 2022. The analyst firm set a price target for $6.00 expecting RNAZ to rise to within 12 months (a possible 1068.22% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年11月15日公布了TransCode Therapeutics（纳斯达克股票代码：RNAZ）的最新目标股价。该分析公司将目标股价定为6.00美元，预计RNAZ将在12个月内升至12个月内（可能上涨1068.22％）。去年有两家分析公司公布了评级。
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
分析师对 TransCode Therapeutics（RNAZ）的最新评级是多少？
The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics maintained their buy rating.
TransCode Therapeutics（纳斯达克股票代码：RNAZ）的最新分析师评级由HC Wainwright & Co. 提供，TransCode Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
TransCode Therapeutics（RNAZ）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与TransCode Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。TransCode Therapeutics的最新评级是在2022年11月15日公布的，因此你应该预计下一个评级将在2023年11月15日左右公布。
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
分析师对 TransCode Therapeutics (RNAZ) 的评级正确吗？
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a maintained with a price target of $10.00 to $6.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.51, which is out of the analyst's predicted range.
尽管评级是主观的，而且会发生变化，但最新的TransCode Therapeutics（RNAZ）评级维持不变，目标股价为10.00美元至6.00美元。TransCode Therapeutics（RNAZ）目前的交易价格为0.51美元，超出了分析师的预期区间。